Description     Claims     Drawing  

US2001049364A   [0004] 
WO2006125073A   [0005] 
EP223958O   [0007] 

World J Gastroenterol   [0003] 
Anticancer Res   [0003] 
Inflamm Bowel Dis   [0003] 
Aliment Pharmacol Ther   [0003] 
Aliment Pharmacol Ther   [0003] 
Carcinogenesis   [0006] 
Aliment Pharmacol Ther   [0006] 
Int'' J Biochem Cell, Biol   [0008] 
J Cell Biol   [0008] 
Methods   [0030] 
Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells   [0039] 
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint   [0039] 
Molecular basis of the potential of mesalazine to prevent colorectal cancer   [0039] 
Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine   [0039] 
Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity   [0039] 
Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells   [0039] 
Down-regulation of mu-protocadherin expression is a common event in colorectal carcinogenesis   [0039] 
Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis   [0039] 
Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia   [0039] 
Colorectal cancer: potential therapeutic benefits of Vitamin D   [0039] 
Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling   [0039] 
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method   [0039]